Document Detail

Strategies for overcoming acquired resistance to epidermal growth factor receptor-targeted therapies in lung cancer.
MedLine Citation:
PMID:  23020725     Owner:  NLM     Status:  In-Data-Review    
Acquired resistance to targeted therapy in epidermal growth factor receptor (EGFR)-mutant lung cancer represents a valuable model for considering strategies of overcoming different types of cellular resistance mechanisms. Using existing data on resistance in EGFR-mutant lung cancer, this review will discuss 3 basic approaches for overcoming resistance to EGFR-targeted therapies: intensification of EGFR inhibition, combination of EGFR inhibitors with other targeted therapies, and changing to anticancer therapies acting via alternate pathways.
Geoffrey R Oxnard
Related Documents :
109185 - Principles of nutritional therapy.
8736725 - Sterilization.
22889865 - Risk and cause of interval colorectal cancer after colonoscopic polypectomy.
7847115 - Bilateral testicular cancer.
18086005 - Dynamic computational modeling in the search for better breast cancer drug therapy.
1933535 - Questionable methods of cancer management. immuno-augmentative therapy (iat).
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Archives of pathology & laboratory medicine     Volume:  136     ISSN:  1543-2165     ISO Abbreviation:  Arch. Pathol. Lab. Med.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-01     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7607091     Medline TA:  Arch Pathol Lab Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1205-9     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Treatment of ALK-Positive Non-Small Cell Lung Cancer.
Next Document:  Advancing personalized cancer medicine in lung cancer.